GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (OTCPK:SHPGF) » Definitions » Debt-to-EBITDA

Shire (SHPGF) Debt-to-EBITDA : 2.64 (As of Sep. 2018)


View and export this data going back to . Start your Free Trial

What is Shire Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Shire's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2018 was $4,249 Mil. Shire's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2018 was $11,098 Mil. Shire's annualized EBITDA for the quarter that ended in Sep. 2018 was $5,809 Mil. Shire's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2018 was 2.64.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Shire's Debt-to-EBITDA or its related term are showing as below:

SHPGF's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.325
* Ranked among companies with meaningful Debt-to-EBITDA only.

Shire Debt-to-EBITDA Historical Data

The historical data trend for Shire's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire Debt-to-EBITDA Chart

Shire Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.23 0.77 9.48 4.13

Shire Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.92 3.31 3.44 3.08 2.64

Competitive Comparison of Shire's Debt-to-EBITDA

For the Biotechnology subindustry, Shire's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shire's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shire's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Shire's Debt-to-EBITDA falls into.



Shire Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Shire's Debt-to-EBITDA for the fiscal year that ended in Dec. 2017 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2788.7 + 16752.4) / 4736.5
=4.13

Shire's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2018 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4248.7 + 11098) / 5809.2
=2.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2018) EBITDA data.


Shire  (OTCPK:SHPGF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Shire Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Shire's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Shire (SHPGF) Business Description

Traded in Other Exchanges
N/A
Address
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Shire (SHPGF) Headlines

From GuruFocus

Chris Davis' Top 3 Buys of the 1st Quarter

By James Li James Li 05-14-2018

Publication of Scheme Document

By Marketwired Marketwired 11-12-2018

4 Stocks John Paulson and Paul Tudor Jones Agree On

By Sydnee Gatewood Sydnee Gatewood 09-21-2018